NOVO NORDISK INVEST 4 A/S

Their core work

Operating through the Steno Diabetes Center in Bagsvaerd (steno.dk), this organization brings clinical metabolic disease research infrastructure to European scientific consortia. Their H2020 work targeted the intersection of metabolic dysfunction and liver pathology — specifically non-alcoholic steatohepatitis (NASH) and alcoholic liver fibrosis — areas where diabetes and liver disease directly overlap. They contribute clinical cohort access, translational research expertise, and metabolic disease knowledge to large multi-country research collaborations. The Novo Nordisk Invest parentage suggests close ties to industrial drug development pipelines for metabolic and hepatic conditions.

What they specialise in

How they've shifted over time

Both H2020 projects started within one year of each other (2015 and 2016), so no meaningful temporal evolution can be traced within this dataset. The two projects are thematically complementary rather than sequential: EPoS addressed metabolic (non-alcoholic) liver damage while GALAXY addressed alcoholic liver disease via the gut-liver axis. No keyword metadata is available to detect finer-grained shifts in focus, and any evolution in their research direction after 2016 is not captured in H2020 records.

With both projects targeting liver pathology from distinct angles — metabolic and alcoholic — they appear to be building cross-cutting expertise across the full spectrum of chronic liver disease, a field with major unmet clinical and pharmaceutical need.

How they like to work

This organization has participated only as a partner, never as a consortium coordinator, indicating they contribute specialist clinical or scientific expertise rather than leading program design. Their two projects generated 25 unique partner relationships across 10 countries, pointing to involvement in large, well-networked European consortia rather than small bilateral collaborations. For consortium builders, they function best as a specialist node bringing clinical metabolic disease infrastructure and patient cohort access.

Connected to 25 unique partners across 10 countries through just 2 projects, averaging roughly 12-13 partners per project — consistent with large RIA consortia with broad European geographic spread.

What sets them apart

The combination of industrial parentage (Novo Nordisk) and a dedicated diabetes clinical center (Steno) gives this organization an unusual bridge between academic liver research and pharmaceutical development pipelines. Both projects address liver conditions directly connected to metabolic syndrome and type 2 diabetes — a disease area where Novo Nordisk holds global leadership. For consortium builders, this means potential access to both patient cohorts and industry translation pathways through a single partner.

Highlights from their portfolio

• EPoS
  The larger of the two projects (EUR 184,256 EC contribution), focused on mechanistic understanding of steatohepatitis — directly relevant to the rapidly growing NASH drug development pipeline.
• GALAXY
  The longer-running engagement (until 2021), targeting the gut-liver axis in alcoholic fibrosis — a topic with increasing clinical and microbiome research relevance.